What they were paid
Olema Pharmaceuticals Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $53,699 | — | $65,688 | — | $119,387 |
| FY2024 | $49,270 | $0 | $200,790 | $0 | $250,060 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Olema Pharmaceuticals, Inc. DEF 14A filed April 29, 2026, accession 0001193125-26-191956, and prior-year filings. Open the filing on EDGAR.
Committees
FY2025 · as the proxy prints themNominating/Governance
The rest of the Olema Pharmaceuticals board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Andrew Rappaport | Independent Director | $121,438 |
| Cynthia Butitta | Independent Director | $126,841 |
| Cyrus L. Harmon, Ph.D | Independent Director | $109,438 |
| Gorjan Hrustanovic, Ph.D | Independent Director | $116,188 |
| Graham Walmsley, M.D., Ph.D | Independent Director | $114,688 |
| Ian Clark | Independent Director | $145,688 |
| Raman (Dr.) | Independent Director | — |
| Sandra Horning, M.D | Independent Director | $118,188 |
| Sean Bohen, M.D., Ph.D | Director | $0 |
| Yi Larson | Independent Director | $125,906 |
The full Olema Pharmaceuticals compensation record
free company briefThis page is one director within Olema Pharmaceuticals's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat